Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The present 16-week double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of lamotrigine add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with treatment-resistant obsessive–compulsive disorder (OCD) receiving serotonin reuptake inhibitors (SRIs). After clinical and neurocognitive assessments, patients were randomly allocated to receive, in a double-blind design, 100 mg/day of lamotrigine or a placebo. A final sample of 33 patients completed the study. The results obtained indicate that lamotrigine added to stable SRI treatment substantially improved obsessive–compulsive (Yale–Brown Obsessive Compulsive Scale: obsessions, p < 0.0001; compulsions, p < 0.0001; total score, p < 0.0001), and affective symptoms (Hamilton Rating Scale for Depression p < 0.0001). Regarding cognitive functions, improvement was observed only in Semantic Fluency ( p = 0.004). The findings provide evidence that lamotrigine augmentation of SRI treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in treatment-resistant OCD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“lamotrigine augmentation of selective serotonin re-uptake inhibitor (SSRI) treatment has been regarded as an effective therapeutic strategy”
From The neurobiological link between OCD and ADHD (2014) · cites this paper as Bruno et al. 2012
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 5×
“The following instruments were used as primary efficacy measures: Y-BOCS (Goodman et al., 1989a, 1989b), Clinical Global Impression-Severity (CGI-S) (Guy, 1976), and Hamilton Rating Scale for Depression (HDRS) (Hamilton, 1960).”
MethodInfluentialDiagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 2×
“Eligible subjects had to have a Y-BOCS total score of 16 or greater (Goodman et al., 1989a, 1989b).”
BackgroundMethodWisconsin Card Sorting Test Manual – Revised and Expanded
Heaton, R. K., Chelune, C., Talley, J., Kay, G., & Curtiss, G. (1981) · Medical Entomology and Zoology · Cited by 2,987
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · cited 2×
“Eligible subjects had to have a Y-BOCS total score of 16 or greater (Goodman et al., 1989a, 1989b).”
BackgroundMethod(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Research works printed but not linked: 7
- Deltito JA, 1994, J Clin Psychiatry, 55, 500
- Goodman WK, 1999, J Clin Psychiatry, 60, 27
- 10.1345/aph.1A102 · doi:10.1345/aph.1a102 · Paper page
- McMeekin H, 2003, J S C Med Assoc, 98, 316
- March J, 1997, J Clin Psychiatry, 58, 1
- Spreen O, 1977, Neurosensory Center Comprehensive Examination For Aphasia (NCCEA)
- Trenerry MR, 1989, Stroop Neuropsychological Screening Test
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive lamotrigine [799,800] 2 Adjunctive memantine [622,781-783] 2”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…topiramate to SSRIs reduces the severity of compulsions [I (PCT)] (Berlin et al., 2011), and of obsessive-compulsive symptoms [I (PCT)] (Mowla et al., 2010); and the addition of lamotrigine to SSRIs reduces the severity of obsessive-compulsive and affective symptoms [I (PCT)] (Bruno et al., 2012).”
BackgroundObsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt, M. E., Bloch, M. H., & Mathews, C. A. (2017) · JAMA · doi:10.1001/jama.2017.2200 · Cited by 493
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
“However, a more recent randomized trial investigated lamotrigine augmentation of stable SSRI treatment and found marked benefit, with 50% responders in the lamotrigine group and none in the placebo group [47].”
BackgroundFineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Metadata
- Authors
- Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A.
- Affiliations
- University of Messina (IT)
- Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Messina, Italy
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-02-20
- Volume
- 26
- Issue
- 11
- Pages
- 1456-1462
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2120585702
- Cited by
- 103
- References
- 56
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 6 · 2018: 12 · 2017: 13 · 2016: 5 · 2015: 11 · 2014: 15 · 2013: 6
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- lamotrigine, treatment-resistant OCD, serotonin reuptake inhibitors, drug augmentation, obsessions and compulsions, depressive symptoms, cognitive function, semantic fluency, tolerability
- MeSH terms
- Lamotrigine, Adult, Aged, Anticonvulsants, Cognition, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales, Triazines, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1177/0269881111431751
- The paper
- Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012). Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. Journal of Psychopharmacology. https://doi.org/10.1177/0269881111431751
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.